Abrdn Life Sciences Investors
HQLFinancial ServicesNASDAQAsset Management
Scan Results
Daily timeframeAbrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe.
Market Cap
—
Beta
0.72
P/E (TTM)
3.11
P/E (Fwd)
—
EPS (TTM)
$6.64
EPS (Fwd)
—
ROE
41.4%
ROA
-0.6%
Cash
$851,602
Total Debt
$0
Free CF
-$4.4M
52W Change
44.8%
Annual Financials
Cash vs Debt
Where HQL stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, HQL finished 20.08% above its 150-day moving average ($17.38) and 23.49% above its 200-day moving average ($16.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HQL overbought or oversold?
At the September 2, 2026 close, HQL's RSI(14) was 53.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Abrdn Life Sciences Investors reports $852K in cash and $0 in total debt. The company is burning cash, with free cash flow at -$4.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 41.4%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from -$103.3M (2022) to $86.4M (2025), reflecting a 184% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HQL.